Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502082 · ClinicalTrials.gov registry record · Phase 1
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
A Phase 1 study, sponsored by Eureka Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04502082: Clinical Trial Phase 1 study, sponsored by Eureka Therapeutics.
NCT04502082 is a Phase 1 study that was terminated before completion, run by Eureka Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04502082, a Phase 1 study, was terminated before completion, sponsored by Eureka Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).
Primary Outcome
Safety of ET140203T cells as assessed by the number of adverse events (AEs) after infusion
Interventions
- BIOLOGICAL ET140203 autologous T cell product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Why NCT04502082 stopped before completion
NCT04502082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which ET140203 autologous T cell product is the first listed.
NCT04502082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04502082 about?
NCT04502082 is a clinical study titled "Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)". Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).
What is the current status of trial NCT04502082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-04-14. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04502082?
The interventions under investigation include: ET140203 autologous T cell product (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502082?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04502082's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI